FirmAtlas
Company handbook · CL · Prepared by FirmAtlas · firmatlas.app · printed 2026-10-16
CL · CIK 21665 · LATEST FILING: 10-Q JUN '26 · FILED JUL 31, 2026
COLGATE-PALMOLIVE COMPANY
$94.11
+1.44 (+1.55%)
Close, Oct 16, 2026 · 52-week $75–99
Last fiscal year
COLGATE-PALMOLIVE COMPANY reported revenue of $20.4B for the year ended Dec 31, 2025 (FY25), up 1.4% from FY24. Net income was $2.1B, operating cash flow $4.2B and free cash flow $3.6B. Source: 10-K filed Feb 23, 2026.
Market cap
$75.4B
P/E
37.0
EV/EBITDA
21.1x
P/B
319.5
Div yield
2.23%
ROIC
34.4%
Revenue 1Y
1.4%/yr
EPS 1Y
−25.1%/yr
Shares 1Y
−1%
Loading chart…
Median
Daily closes, split-adjusted · ratios at each fiscal year end
Company
CEONoel Wallace
HQNew York, NY
AuditorPricewaterhouseCoopers LLP
Employees33,600
Year endsDecember
Revenue by segment · FY25
Oral Personal And Home Care77%
Pet Nutrition23%
Compounded growth & averages
10Y
5Y
3Y
TTM
Share price
2.7%
4.3%
9.3%
20.5%
Upgrade to see 10 years
Share price: yearly compound rate of the traded close; the last column is the past year.
Where the cash went · FY24–FY25
$8.0B deployed
Capex
$1.1B
14.1%
Acquisitions
$293M
3.7%
Dividends
$3.6B
45.3%
Buybacks
$2.9B
37.0%
Operating cash flow over the period: $8.3B. Total debt changed by +$1.3B. R&D of $721M is already inside operating costs.
Growth engines
How much of the profit growth came from new investment, and how much from running the business better.
Upgrade to see 10 years
Financials
Last 2 years · Upgrade to see 10 years · USD millions · each year opens its 10-K · change vs previous year
Last 4 quarters · USD millions · quarter-end month shown · change vs same quarter a year earlier
TTM = the last four quarters, to Jun '26. Balance-sheet rows show that latest quarter. “—” where the quarters do not add up to the annual figures. No TTM for cash: our quarterly rows do not hold short-term investments yet, and annual cash includes them.
Income
Revenue
20,101
20,382+1.4%
21,046
YoY
+1.4%
Gross profit
12,161
12,251+0.7%
12,717
Gross margin
60.5%
60.1%−0.4 pp
—
Operating income
4,268
3,306−22.5%
3,130
Operating margin
21.2%
16.2%−5.0 pp
—
EBITDA
4,873
3,936−19.2%
—
EBITDA margin
24.2%
19.3%−4.9 pp
—
Interest expense
292
267−8.6%
—
Interest coverage
16.69x
14.74x−1.95x
—
Net income
2,889
2,132−26.2%
2,038
YoY
−26.2%
Net margin
14.4%
10.5%−3.9 pp
—
EPS (diluted, $)
3.51
2.63−25.1%
2.53
YoY
−25.1%
Balance sheet
Total assets
16,046
16,330+1.8%
16,790
Cash & short-term investments
1,256
1,395+11.1%
—
Accounts receivable
1,521
1,675+10.1%
—
Inventory
1,987
2,032+2.3%
—
Net PP&E
4,422
4,660+5.4%
—
Other assets
6,860
6,568−4.3%
—
Total liabilities
15,834
16,276+2.8%
16,554
Accounts payable
1,805
2,089+15.7%
—
Total debt
7,657
8,954+16.9%
7,823
Other liabilities
6,372
5,233−17.9%
—
Shareholders’ equity
212
54−74.5%
236
Total liabilities = total assets − shareholders’ equity, so it includes minority interest where a company has one.
Cash flow statement · as filed
Cash from operations
4,107
4,198+2.2%
4,456
Net income
3,049
2,261−25.8%
—
Depreciation & amortization
605
630+4.1%
—
Stock-based compensation
135
155+14.8%
—
Working capital & other
318
1,152+262.3%
—
Cash from investing
(534)
(817)n/m
—
Capex
(561)
(564)n/m
—
Acquisitions
0
(293)n/m
—
Investments bought
(574)
(698)n/m
—
Investments sold / matured
564
752+33.3%
—
Other investing
37
(14)−137.8%
—
Cash from financing
(3,389)
(3,256)n/m
—
Dividends
(1,789)
(1,823)n/m
—
Buybacks
(1,739)
(1,210)n/m
—
Shares issued
638
101−84.2%
—
Other financing
(499)
(324)n/m
—
Net change in cash
130
192+47.7%
—
Free cash flow (OCF − capex)
3,546
3,634+2.5%
3,858
Where the cash went
Operating cash flow
4,107
4,198+2.2%
4,456
Reinvested in the business
561
857+52.8%
—
% of operating cash flow
13.7%
20.4%
Capex
561
564+0.5%
598
Acquisitions
0
293n/m
—
R&D (memo, already in costs)
355
366+3.1%
—
Free cash flow
3,546
3,634+2.5%
3,858
YoY
+2.5%
Returned to shareholders
3,528
3,033−14.0%
—
% of free cash flow
99.5%
83.5%
Dividends
1,789
1,823+1.9%
—
Buybacks
1,739
1,210−30.4%
—
Change in total debt
—
1,297
—
Cash left over
—
1,605
—
FCF conversion (FCF ÷ net income)
122.7%
170.5%+47.7 pp
—
Owner earnings
—
2,283
—
Owner earnings margin
—
11.2%
—
Buyback yield
2.4%
1.9%−0.4 pp
—
Returns & ratios
ROIC (all capital)
49.7%
34.4%−15.4 pp
—
ROIC (operating)
53.7%
39.4%−14.3 pp
—
Net debt / EBITDA
1.31x
1.92x+0.61x
—
Debt / equity
36.12x
165.81x+129.70x
—
Cash conversion cycle (days)
36
27−9 d
—
ROE
1362.7%
3948.1%+2585.4 pp
—
ROA
18.0%
13.1%−4.9 pp
—
ROCE
41.5%
34.9%−6.6 pp
—
NOPAT
3,289
2,444−25.7%
—
Invested capital (operating)
6,125
6,278+2.5%
—
Invested capital (all)
6,613
7,613+15.1%
—
Reinvestment rate
—
6.3%
—
Debtor days
28
30+2 d
—
Inventory days
91
91−0 d
—
Days payable
83
94+11 d
—
Income
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
5,131
5,230
5,324
5,361
vs year-ago quarter
Gross profit
3,049
3,146
3,226
3,296
Gross margin
59.4%
60.2%
60.6%
61.5%
Operating income
1,059
91
964
1,016
Net income
735
(36)
646
693
vs year-ago quarter
Net margin
14.3%
−0.7%
12.1%
12.9%
EPS (diluted, $)
0.91
−0.04
0.80
0.86
vs year-ago quarter
Balance sheet
Sep '25
Dec '25
Mar '26
Jun '26
Total assets
17,513
16,330
16,610
16,790
Cash & equivalents
1,279
1,395
1,335
1,370
Total debt
7,306
8,954
7,937
7,823
Shareholders’ equity
856
54
145
236
Cash flow
Sep '25
Dec '25
Mar '26
Jun '26
Operating cash flow
1,261
1,453
747
995
Capex
155
177
138
128
Free cash flow
1,106
1,276
609
867
vs year-ago quarter